Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cyclacel Pharmaceuti (CYCC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,122
  • Shares Outstanding, K 17,199
  • Annual Sales, $ 150 K
  • Annual Income, $ -7,290 K
  • 60-Month Beta 3.51
  • Price/Sales 82.23
  • Price/Cash Flow N/A
  • Price/Book 0.59
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.63
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/13/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.150 on 07/13/16
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year -0.12
  • Growth Rate Est. (year over year) -58.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.67 +5.99%
on 04/18/19
1.18 -39.82%
on 03/25/19
-0.24 (-25.25%)
since 03/22/19
3-Month
0.67 +5.99%
on 04/18/19
1.18 -39.82%
on 03/25/19
-0.02 (-2.73%)
since 01/23/19
52-Week
0.51 +39.24%
on 12/24/18
1.87 -62.03%
on 09/05/18
-0.73 (-50.69%)
since 04/23/18

Most Recent Stories

More News
New Research: Key Drivers of Growth for Conatus Pharmaceuticals, MasTec, Cyclacel Pharmaceuticals, Melinta Therapeutics, North American Construction Group, and B.O.S. Better Online Solutions -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Conatus Pharmaceuticals Inc....

CNAT : 0.78 (+3.85%)
MLNT : 4.59 (+7.24%)
NOA : 12.98 (-0.08%)
MTZ : 52.53 (+0.34%)
BOSC : 2.60 (+0.39%)
CYCC : 0.71 (+0.75%)
Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced Phase 1 clinical...

CYCCP : 5.25 (-0.46%)
CYCC : 0.71 (+0.75%)
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

- Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT -

CYCC : 0.71 (+0.75%)
Cyclacel Provides Clinical Development Update and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com

LOS ANGELES, CA / ACCESSWIRE / March 26, 2019 / , The Official MicroCap News Source™, today published an SNNLive Video Interview with Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, Inc....

CYCC : 0.71 (+0.75%)
Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor

-- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism

CYCCP : 5.25 (-0.46%)
CYCC : 0.71 (+0.75%)
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth...

CYCC : 0.71 (+0.75%)
Cyclacel to Participate in 31st Annual ROTH Conference March 18-19

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it will participate...

CYCCP : 5.25 (-0.46%)
CYCC : 0.71 (+0.75%)
Biotech Companies Turn Their Attention to Cancer as Global Incidences Grow

In 2018, cancer was the second leading cause of death around the globe. Cancer was responsible for an estimated 9.6 million deaths in that year, or approximately one in six deaths, according to the World...

CANF : 0.50 (unch)
CYCC : 0.71 (+0.75%)
ONCS : 0.59 (+4.76%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0240 (unch)
BLRX : 0.37 (-2.53%)
Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that an abstract...

CYCCP : 5.25 (-0.46%)
CYCC : 0.71 (+0.75%)
Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that...

CYCC : 0.71 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CYCC with:

Business Summary

CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside...

See More

Key Turning Points

2nd Resistance Point 0.74
1st Resistance Point 0.73
Last Price 0.71
1st Support Level 0.69
2nd Support Level 0.66

See More

52-Week High 1.87
Fibonacci 61.8% 1.35
Fibonacci 50% 1.19
Fibonacci 38.2% 1.03
Last Price 0.71
52-Week Low 0.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar